Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon levels. It is unique among DPP-4 inhibitors as it is primarily excreted via the biliary/gastrointestinal tract.
## Primary Indications
Type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control.
## Adult Dosing
* **Standard dose:** 5 mg orally once daily.
* **Maximum dose:** 5 mg daily.
## Pediatric Dosing
Safety and effectiveness have not been established in patients younger than 18 years.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment necessary.
* **Hepatic Impairment:** No dose adjustment necessary.
## Contraindications
* History of hypersensitivity to linagliptin (e.g., anaphylaxis, angioedema, urticaria).
* Type 1 diabetes or treatment of diabetic ketoacidosis.
## Adverse Effects
* **Common:** Nasopharyngitis.
* **Serious (Rare):** Pancreatitis (discontinue immediately if suspected), bullous pemphigoid, severe arthralgia, hypersensitivity reactions.
* **Hypoglycemia:** Low risk when used as monotherapy; risk increases when used with insulin or insulin secretagogues (e.g., sulfonylureas).
## Key Drug Interactions
* **P-glycoprotein/CYP3A4 Inducers (e.g., Rifampin):** May decrease linagliptin efficacy if strong inducers are used chronically; monitor glycemic control.
* **Insulin/Sulfonylureas:** Enhanced hypoglycemic effect. Consider dose reduction of the insulin or secretagogue.
## Monitoring
* **Glycemic Control:** HbA1c (typically every 3–6 months) and self-monitored blood glucose.
* **Symptomatic Monitoring:** Monitor for signs of pancreatitis (persistent, severe abdominal pain) and worsening skin lesions.
## Clinical Pearls
* Linagliptin is not metabolized by the kidneys, making it a preferred choice in patients with significantly impaired renal function.
* Does not require weight-based adjustments or titration.
* Can be taken with or without food.
* Discontinue if severe joint pain occurs; symptoms often resolve after discontinuation.
***
**Disclaimer:** This information is for educational purposes only. Drug dosing, contraindications, and interaction profiles may change. Always verify current prescribing information via clinical decision support tools (e.g., Lexicomp, UpToDate) or the manufacturer’s package insert before prescribing or administering medication.
